Committee for Medicinal Products for Human Use of the European Medicine Agency Recommends FAMPYRA to Adult Patients with Multiple Sclerosis
Tweet
Share
E-mailGet Alerts ACOR Hot Sheet
Join SI Premium – FREE
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that The Committee for Medicinal Products for Human Use of the European Medicine Agency has recommended conditional marketing authorization of FAMPYRA for the improvement of walking in adult patients with multiple sclerosis with walking disability.
This oral therapy was developed and is commercialized by Acorda Therapeutics, Inc. in the United States under the trade name AMPYRA Extended Release Tablets. FAMPYRA is being developed and marketed by Biogen Idec (Nasdaq: BIIB) outside the United States under a licensing agreement from Acorda.
Based on the CHMP recommendation, Biogen Idec expects that a conditional marketing authorization for FAMPYRA should be granted within 67 days.
As part of the license agreement between Acorda and Biogen Idec, European Medicines Agency approval in Europe triggers a $25 million milestone payment to Acorda from Biogen Idec. Acorda may receive additional payments of up to $375 million based on the successful achievement of future regulatory and sales milestones. Under Acorda’s existing agreements with
This oral therapy was developed and is commercialized by Acorda Therapeutics, Inc. in the United States under the trade name AMPYRA Extended Release Tablets. FAMPYRA is being developed and marketed by Biogen Idec (Nasdaq: BIIB) outside the United States under a licensing agreement from Acorda.
Based on the CHMP recommendation, Biogen Idec expects that a conditional marketing authorization for FAMPYRA should be granted within 67 days.
As part of the license agreement between Acorda and Biogen Idec, European Medicines Agency approval in Europe triggers a $25 million milestone payment to Acorda from Biogen Idec. Acorda may receive additional payments of up to $375 million based on the successful achievement of future regulatory and sales milestones. Under Acorda’s existing agreements with
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sky Quarry names Heidi Bowman as CFO
- Scholar Rock updates apitegromab regulatory status in U.S., Europe, Japan
- WiMi proposes quantum convolutional neural network for data tasks
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
